
LXEO
Healthcare · Biotechnology · $235.6M market cap
$2.87-0.04 (-1.4%)Nov 13, 4:00 PM EST
Next report
Time not confirmed
Analyst consensus
Fiscal period ending Sep 30, 2026
EPS trend, 90 days to now · -7.1% over 90 days · 30-day revisions 1 up, 2 down
Beat estimates in 3 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 18, 2026 · upcoming | Time not confirmed | -0.33 | -0.33 | 0.0% |
| Aug 12, 2026 | Before the open | -0.30 | -0.30 | 0.0% |
| May 11, 2026 | Before the open | -0.30 | -0.25 | +16.7% |
| Mar 16, 2026 | Time not confirmed | -0.86 | -0.27 | +68.6% |
| Nov 5, 2025 | Before the open | -0.48 | -0.33 | +31.3% |
| Aug 14, 2025 | Before the open | -0.66 | -0.68 | -3.0% |
| May 12, 2025 | Before the open | -0.77 | -0.99 | -28.6% |
| Mar 24, 2025 | Time not confirmed | -0.72 | -0.78 | -8.3% |
| Nov 13, 2024 | Before the open | -0.67 | -0.89 | -32.8% |
| Aug 12, 2024 | Before the open | -0.69 | -0.64 | +7.2% |
| May 9, 2024 | Before the open | -0.79 | -0.77 | +2.5% |
| Mar 11, 2024 | Before the open | -0.73 | -0.85 | -16.4% |
| Dec 11, 2023 | Before the open | -3.02 |
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional…
| -1.20 |
| +60.3% |